To identify the essential role of Wnt/β-Catenin pathway in USP21/G3BP1 axis-regulated ESCC progression, IWR-1, an inhibitor for Wnt/β-Catenin signaling, was applied to treat KYSE-150 cells with USP21 overexpression, while laduviglusib, an activator for Wnt/β-Catenin signaling, was added into culture medium of KYSE-150 cells with USP21 depletion. Here, USP21 is linked to esophageal squamous cell carcinoma.